Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. US Stem Cell's Goodwill for the quarter that ended in Dec. 2022 was $0.00 Mil. US Stem Cell's Total Assets for the quarter that ended in Dec. 2022 was $0.07 Mil.
Therefore, US Stem Cell's Goodwill to Asset Ratio for the quarter that ended in Dec. 2022 was 0.00.
US Stem Cell Goodwill-to-Asset Historical Data
The historical data trend for US Stem Cell's Goodwill-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's Goodwill-to-Asset
For the Biotechnology subindustry, US Stem Cell's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Goodwill-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Goodwill-to-Asset falls into.
US Stem Cell Goodwill-to-Asset Calculation
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
US Stem Cell's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (OTCPK:USRM) Goodwill-to-Asset Explanation
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
US Stem Cell Goodwill-to-Asset Related Terms
Thank you for viewing the detailed overview of US Stem Cell's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 